Japan Pharma Market Down 1.7% in 2018, with Maviret as Top-Selling Product: IQVIA Data

The Japanese ethical drug market decreased 1.7% to 10,337,471 million yen on an NHI price basis in 2018 marking a year-on-year drop for a second year-running, according to data released by market research firm IQVIA. By product, AbbVie’s hepatitis C...read more